Oncopeptides AB (LTS:0RN4) FFO


LTS:0RN4 Oncopeptides AB LTS:0RN4
46 GF Score
Price kr1.66
GF Value kr4.23
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Oncopeptides AB FFO?

FFO (Funds from operations) only applies to REITs.

LTS:0RN4
46GF Score
Oncopeptides AB LTS:0RN4
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Oncopeptides AB (LTS:0RN4) Overvalued in 2026?

Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued. The current stock price of kr1.66 is trading 60.8% below its estimated GF Value™ of kr4.23. GuruFocus considers Oncopeptides AB to be Possible Value Trap.

Key valuation signals for LTS:0RN4:

  • FFO:
  • GF Value™: kr4.23 vs. price of kr1.66 (60.8% below fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RN4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncopeptides AB Business Description

Address Luntmakargatan 46, Stockholm, SWE, SE-111 37
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
46GF Score

Get the complete analysis for LTS:0RN4

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.66
Price
kr4.23
GF Value